Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCKBR | P32239 | 11/20 | 0.38 |
| ▸ | CCKAR | P32238 | 6/20 | 0.38 |
| ▸ | LIMK2 | P53671 | 2/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.31 |
| ▸ | GHSR | Q92847 | 1/20 | 0.30 |
| ▸ | ACLY | P53396 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5728245 | 1.00 | CCKBR (0.38) | CCKBRCCKARLIMK2L3MBTL1GAA | |
| SCHEMBL3902088 | 0.92 | CCKBR (0.33) | CCKBRCCKAR | |
| SCHEMBL5728424 | 0.91 | LIMK2 (0.36) | LIMK2EGLN1GHSRACLY | |
| SCHEMBL3900580 | 0.91 | LIMK2 (0.36) | LIMK2EGLN1GHSRACLY | |
| SCHEMBL3902462 | 0.91 | LIMK2 (0.38) | LIMK2EGLN1GHSR | |
| SCHEMBL5443012 | 0.91 | CCKBR (0.36) | CCKBRCCKARLIMK2EGLN1ACLY | |
| SCHEMBL3900502 | 0.91 | CCKBR (0.36) | CCKBRCCKARLIMK2EGLN1ACLY | |
| SCHEMBL3902484 | 0.91 | CCKBR (0.36) | CCKBRCCKARLIMK2EGLN1ACLY | |
| SCHEMBL3900162 | 0.88 | USP2 (0.35) | LIMK2ACLY | |
| SCHEMBL3904144 | 0.86 | L3MBTL1 (0.47) | CCKBRCCKARL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7241759-B2 | Benzo[1,2,5]thiadiazole compounds | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-07-10 | — | — | US | claimed |
| US-7550492-B2 | Benzo[1,2,5]thiadiazole compounds | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-06-23 | — | — | US | disclosed |
| US-20070276016-A1 | BENZO[1,2,5]THIADIAZOLE COMPOUNDS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-11-29 | — | — | US | disclosed |
| US-7241759-B2 | Benzo[1,2,5]thiadiazole compounds | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-07-10 | — | — | US | disclosed |
| US-20040224983-A1 | Benzo[1,2,5]thiadiazole compounds | JANSSEN PHARMACEUTICA, N.V. (BE) | 2004-11-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070276016-A1 | BENZO[1,2,5]THIADIAZOLE COMPOUNDS | CCKBR, CCKAR, GIPR | CCKBR 1/4885CCKAR 2/4885LIMK2 1140/4885 |
| US-20040224983-A1 | Benzo[1,2,5]thiadiazole compounds | CCKBR, CCKAR, BRSK2 | CCKBR 1/4885CCKAR 2/4885LIMK2 921/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.